Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views

The document reviewed the challenges and strategies in targeting Wnt signaling for gastrointestinal cancer therapy. It emphasized the complexity of Wnt signaling and the difficulty in targeting it due to its essential role in normal tissue homeostasis, which could lead to severe side effects. The review discussed various agents in clinical trials, such as ipafricept and vantictumab, which showed varying degrees of adverse events and partial responses. It highlighted the importance of designing specific and effective Wnt targeting strategies, including focusing on cancer- or tissue-specific components and exploring combination therapies to enhance efficacy while minimizing side effects. Despite the risks, targeting Wnt signaling was considered a promising avenue for cancer therapy, with ongoing efforts to improve drug specificity and expand treatable cases.